UNSPSC 51171970: Zolenzepine

This classification denotes an anti-ulcer agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O0XJ4L38Z3. European Medicines Agency schedules Zolenzepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00177MIG. Zolenzepine generally arises in the molecular formula C19H24N6O2.

UNSPSC 51171970 Zolenzepine, a Commodity code, nominally describes a pharmaceutical active ingredient, but the recent state and local solicitations tagged under this code do not involve zolenzepine specifically. Instead, the code appears in procurement records for offender drug testing services, therapeutic pharmacy initiatives, and generic multi-source pharmaceutical distribution — none of which center on zolenzepine as a procured product. The three recent opportunities span specimen collection and immunoassay drug screening, a Texas HHS request for information on direct-to-manufacturer prescription programs, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) contract for generic and OTC pharmaceutical products through authorized wholesalers. The issuing bodies include county correction departments (Collin County Community Supervision and Corrections Department), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing vehicles (MMCAP, administered by the Minnesota Department of Administration).

Recent activity concentrates in Texas and Minnesota. Collin County posted RFP 2026-327 for Offender Specimen Collection and Drug Testing Services on July 9, 2026, due July 23, 2026, with an estimated annual value of $600,000 covering approximately 25,031 tests annually across two sites in Plano and McKinney, laboratory certification requirements under SAMHSA or Texas DPS, and a contract term of two years with three optional one-year renewals. The Minnesota Department of Administration issued MMCAP RFP S1070000015802 on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, effective July 1, 2026, with two-year initial terms and 3 percent administrative fees. Texas HHS posted Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with no award value or formal timeline specified at that exploratory stage. The code shows little relevant recent activity focused on zolenzepine as a distinct procurement item.